Glaukos Corporation has released a presentation outlining its core growth strategies and recent advancements. The company highlighted its focus on innovation, with significant investment in research and development since 2018 and the expansion of its pipeline to 14 disclosed ocular programs in 2025. Glaukos showcased five novel technology platforms, including micro-scale surgical devices, sustained-release and bio-activated pharmaceuticals, transdermal pharmaceuticals, and bio-erodible intravitreal therapies. The presentation covered four therapeutic areas: glaucoma, rare diseases such as keratoconus, anterior segment conditions, and posterior segment diseases. Key commercial catalysts for 2025-26 include methodical launches of interventional glaucoma therapies and new treatments for keratoconus. The company also reported progress in expanding market access and clinical evidence for its products. You can access the full presentation through the link below.